With about 85% of the proteome currently undrugged, accessing these targets that are, at present, extremely difficult to drug, has prevented researchers from achieving desired clinical successes.

The 2nd Proteome- Targeted Drug Discovery Summit will unite large pharma and innovative biotech, as well as key opinion leaders in academia, to develop robust structural and biochemical tools to open up the full therapeutic opportunity held within the entire proteome. Identify and validate novel druggable sites and optimize structure-guided fragment-based drug design of small molecules with improved potency, selectivity, and physio-chemical properties.

Join the leading experts from the biopharmaceutical industry and academia to enhance your existing structural, chemical and computational toolbox and explore how these innovative technologies can be uniquely employed to target the entire proteome and advance your small molecule drug discovery pipeline.

Key Reasons to Attend Include

• Utilize next-generation chemical biology platforms for novel target target identification with insights from Biogen, Merck & AstraZeneca
• Expand the druggable proteome through next-generation screening platforms, with insight from GSK, PhoreMost & Ribon Therapeutics
• Leverage innovative chemical probes to accelerate fragment-based lead generation, with insights from Novartis & The Weizmann Institute of Science
• Harness structure-based computational technologies to successfully target protein-protein interactions, with insights from RAPT Therapeutics
• Give rise to novel therapeutic modalities to drug the undruggable, with insights from Silicon Therapeutics& AbbVie

To know more about 2nd Annual Proteome- Targeted Drug Discovery Summit please click here.